ArticleIranian journal of biotechnology2025
Comprehensive Bioinformatic Analysis Reveals Survival-Associated Hub Genes and MicroRNAs in Multiple Myeloma Patients.
Article in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a B-cell malignancy characterized by clonal plasma cell proliferation in the bone marrow. Although significant advances have been achieved in treatment, it remains largely incurable, and fundamental insights at the molecular level remain to be obtained. Objecteves: This study aimed to identify key genes and microRNA (miRNA) involved in multiple myeloma by re-analyzing transcriptomic datasets. We sought to determine differentially expressed genes and miRNAs, perform pathway and network analyses, and highlight their roles in disease progression, prognosis, and therapeutic resistance. Materials and Methods: We identified and characterized the hub genes and miRNAs associated with MM by re-analyzing three microarray datasets, GSE16558, GSE141260, and GSE146649, using high-throughput sequencing. We re-identified DEGs using a strict filtering criterion: |logFC| ≥ 1 and p-value < 0.05. The application of the Venn diagram analysis highlighted 13 common DEGs among the datasets. A total of 3211 differentially expressed genes (DEGs) and 25 differentially expressed microRNAs (DEMs) were screened out, Thereafter, GO and pathway enrichment of the DEGs were analyzed using FunRich software, involving biological processes, cellular components, and molecular functions. The PPI network was constructed using the Cytoscape software to determine the interactions among these DEGs. Results: Our analyses underlined several key biological processes, including the migration of immune cells, lymphocyte activation, and TGF-β signaling pathways, which play crucial roles in the progression of MM. The PPI network identified a number of hub genes; among these, CCND1, ITGB1, and CREB1 were significantly associated with patient survival outcomes. In addition, the interaction predictions indicated an important function of miR-34c-5p and miR-155-5p in governing apoptosis, thereby promoting drug resistance in MM cells. We identified 13 common DEGs across datasets, with key enrichments in immune cell migration, lymphocyte activation, and TGF-β signaling. PPI analysis revealed CCND1, ITGB1, and CREB1 as top hub genes, significantly linked to survival outcomes. MiRNA interactions, particularly miR-34c-5p and miR-155-5p, were implicated in apoptosis and drug resistance. Conclusion: These data highlight the complex interplay between genetic alterations and the immune microenvironment in MM, opening new prospects for biomarkers and therapeutic targets that may hopefully improve patient management, treatment strategies, prognosis, and therapeutic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.